Înapoi la știri

Micron: The Boom And Bust Memory Cycle Could Finally Be Dead (NASDAQ:MU) - Seeking Alpha

58 minute în urmă
3 minute min
Maria Simionescu
Stock IdeasLong IdeasTech Micron: The Boom And Bust Memory Cycle Could Finally Be DeadJul 28, 2026, 11:30 AM ETMicron Technology, Inc. (MU) Stock, MU:CA Stock, ZMIC:CA Stock83 Comments5 LikesSteven Fiorillo42.44K FollowersFollowSummaryMicron is transforming from a cyclical commodity business to a contracted model, underpinned by 16 take-or-pay agreements through 2030 covering ~$100B in minimum revenue.Q3 2026 was a record quarter: $41.46B revenue (+346% YoY), 84.9% gross margin, $25.11 EPS, and a net cash position of $24.4B.MU trades at I've been covering the markets long enough to know how memory cycles are supposed to end. There are many investors who classify Micron Technology, Inc. (MU) as a cyclical stock because of how traditional Analyst’s Disclosure: I/we have a beneficial long position in the shares of GOOGL, ORCL, MSFT, AMZN, NVDA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Disclaimer: I am not an investment advisor or professional. This article is my own personal opinion and is not meant to be a recommendation of the purchase or sale of stock. The investments and strategies discussed within this article are solely my personal opinions and commentary on the subject. This article has been written for research and educational purposes only. Anything written in this article does not take into account the reader’s particular investment objectives, financial situation, needs, or personal circumstances and is not intended to be specific to you. Investors should conduct their own research before investing to see if the companies discussed in this article fit into their portfolio parameters. Just because something may be an enticing investment for myself or someone else, it may not be the correct investment for you. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Alte postari din Economie
Economie

Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug - STAT

STAT Plus: Pharma’s drug spending deflection By Bob Herman Biotech Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug Capricor had previously said its drug, called deramiocel, hit its targets in a Phase 3 study Manage alerts for this article Email this article Share this article Sarah Silbiger/Getty Images By Jason Mast Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77.

Economie

ChatGPT medical advice brought man 'to brink of death', lawsuit alleges - BBC

ShareSaveAdd as preferred on GoogleSean SeddonEPAA 55-year-old American claims he was repeatedly misdiagnosed by the AI tool prior to a medical emergency A man who claims medical advice from ChatGPT "brought him to the brink of death" has sued OpenAI, the company behind the popular chatbot, and its founder Sam Altman. A lawsuit filed by Scott Winters, a 55-year-old pastor from Florida, claimed ChatGPT told him not to seek medical help after repeatedly asking about symptoms in the build-up to a near-fatal pulmonary embolism.

Acasa Recente Radio Județe